DGIdb - FCGR3A Gene Record

FCGR3A 2214 Druggable Genome

Alternate Names:

2214
FC FRAGMENT OF IGG RECEPTOR IIIA
FCGR3A
CD16
CD16A
FCG3
FCGR3
FCGRIII
FCR-10
FCRIII
FCRIIIA
IGFR3
IMD20
146740
3619
ENSG00000203747
OTTHUMG00000034466
PA28065
P08637
BE0002097
Immunoglobulin gamma Fc receptor IIIA
T59001
3017
NM_000569
NP_000560

Gene Info:

Gene Biotype	PROTEIN_CODING
GuideToPharmacology Gene Category Name	CD molecules
GuideToPharmacology Gene Category ID	852
GuideToPharmacology Gene Category Name	Immunoglobulin like domain containing proteins
GuideToPharmacology Gene Category ID	984

(5 More Sources)

Gene Categories: Category Details

EXTERNAL SIDE OF PLASMA MEMBRANE
DRUGGABLE GENOME

Publications:

Negri FV et al., 2014, Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy., Pharmacogenomics J
Morgen EK et al., 2017, Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis., Pharmacogenomics J
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Zhang et al., 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab., J. Clin. Oncol.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Magnes T et al., 2018, The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab., Pharmacogenomics J
Shepshelovich D et al., 2018, Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer., Cancer Med
Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology
Fujita et al., 2007, Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil., Intern. Med.
Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
Hofmann HP et al., 2016, Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®))., Expert Opin Biol Ther
Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
Varchetta et al., 2007, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2., Cancer Res.
Musolino A et al., 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer., J Clin Oncol
Tamura K et al., 2011, FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer., Ann Oncol
Suzuki et al., 2007, A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients., Clin. Cancer Res.
Lin et al., 2005, FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia., Blood
Harris et al., 1989, Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor., J. Immunol.
Smyth et al., 1991, IL-8 gene expression and production in human peripheral blood lymphocyte subsets., J. Immunol.
Wang Y et al., 2004, Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro., Angiogenesis
Maes et al., 2007, Comparison of sample fixation and the use of LDS-751 or anti-CD45 for leukocyte identification in mouse whole blood for flow cytometry., J. Immunol. Methods
Nishio M et al., 2009, FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation., Eur J Haematol
Kim SH et al., 2015, Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab., JAMA Neurol
Hatjiharissi et al., 2007, Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy., Clin Lymphoma Myeloma
Quartuccio L et al., 2014, The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study., Ann Rheum Dis
Jiménez Morales A et al., 2019, FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis., J Clin Pharmacol
Weng WK et al., 2003, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma., J Clin Oncol
Niwa et al., 2004, Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism., Clin. Cancer Res.
Kim et al., 2006, FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma., Blood
Baj et al., 1992, T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment., Arch. Immunol. Ther. Exp. (Warsz.)
Edwards et al., 1995, Evidence for a dithiol-activated signaling pathway in natural killer cell avidity regulation of leukocyte function antigen-1: structural requirements and relationship to phorbol ester- and CD16-triggered pathways., Blood
Indraccolo et al., 1993, Standardization of in vitro synthesis and detection of HIV-1-specific antibodies., J. Immunol. Methods
László et al., 2001, Increased histidine decarboxylase expression during in vitro monocyte maturation; a possible role of endogenously synthesised histamine in monocyte/macrophage differentiation., Inflamm. Res.
Paciucci et al., 1991, Immunotherapy with IL2 by constant infusion and weekly doxorubicin., Am. J. Clin. Oncol.
Schomburg et al., 1992, Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma., Mol. Biother.
Takahashi et al., 2007, Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells., Scand. J. Immunol.
Tsukahara S et al., 2008, A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis., Ann Rheum Dis
Montes A et al., 2015, FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors., Pharmacogenomics
Hiatt A et al., 2014, Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy., Proc Natl Acad Sci U S A
Yeager et al., 2002, Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans., Anesth. Analg.
Vendemiale et al., 1992, Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results., Arzneimittelforschung
Vaishnaw et al., 2002, Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration., J Pharmacokinet Pharmacodyn
da Silva et al., 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells., J. Immunol.
Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
Laviolette M et al., 2013, Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia., J Allergy Clin Immunol
Wang B et al., 2017, Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma., CPT Pharmacometrics Syst Pharmacol
Ghazi A et al., 2012, Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma., Expert Opin Biol Ther
Seimetz D et al., 2010, Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy., Cancer Treat Rev

TESMILIFENE HYDROCHLORIDE FCGR3A

Interaction Score: 3.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11556524

Sources:
NCI
BENRALIZUMAB FCGR3A

Interaction Score: 2.37

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
23866823 28109128 22136436

Sources:
DrugBank
ALEFACEPT FCGR3A

Interaction Score: 2.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12795239 11970990 17139284 17016423

Sources:
DrugBank
RITUXIMAB FCGR3A

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19018870 26167726 17324336 23505228 30457672 12975461 15448014 16609067

Sources:
PharmGKB
LACTULOSE FCGR3A

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1418064

Sources:
NCI
PALIVIZUMAB FCGR3A

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423 24711420

Sources:
DrugBank
TOCILIZUMAB FCGR3A

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30457672

Sources:
PharmGKB
MAFOSFAMIDE FCGR3A

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1515095

Sources:
NCI
PENICILLIN G POTASSIUM FCGR3A

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17257217

Sources:
NCI
ETANERCEPT FCGR3A

Interaction Score: 0.57

Interaction Types & Directionality:

ligand

Interaction Info:

PMIDs:
15526004 27463856 19128982 15457442 24048425 27044681

Sources:
PharmGKB DrugBank
ADALIMUMAB FCGR3A

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423 24048425 27044681

Sources:
PharmGKB
CATUMAXOMAB FCGR3A

Interaction Score: 0.44

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
20347527

Sources:
DrugBank
INFLIXIMAB FCGR3A

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19005160 25823782 24048425 27044681

Sources:
PharmGKB
ALEMTUZUMAB FCGR3A

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15217834

Sources:
DrugBank
TRASTUZUMAB FCGR3A

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18089830 18347005 21109570 17363544

Sources:
NCI PharmGKB
DACLIZUMAB FCGR3A

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423

Sources:
DrugBank
CETUXIMAB FCGR3A

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23296156 27897268 17139284 17704420 17016423 28719596 30318772

Sources:
NCI PharmGKB DrugBank
SARILUMAB FCGR3A

Interaction Score: 0.3

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
CIMETIDINE FCGR3A

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11556524

Sources:
NCI
SODIUM CHLORIDE FCGR3A

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17187818

Sources:
NCI
GELDANAMYCIN FCGR3A

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7662976

Sources:
NCI
ALDESLEUKIN FCGR3A

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2528593 1827816

Sources:
NCI
EPOETIN ALFA FCGR3A

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1300984

Sources:
NCI
PUROMYCIN FCGR3A

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8423352

Sources:
NCI
BEVACIZUMAB FCGR3A

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17139284 17016423 15886877

Sources:
DrugBank
PREDNISOLONE FCGR3A

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17329922

Sources:
NCI
FENTANYL FCGR3A

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11772808

Sources:
NCI
THALIDOMIDE FCGR3A

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15457133

Sources:
NCI
HEPARIN FCGR3A

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18492254

Sources:
NCI
INDOMETHACIN FCGR3A

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17329922

Sources:
NCI
CYCLOSPORINE FCGR3A

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17852453

Sources:
NCI
DOXORUBICIN FCGR3A

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1830717

Sources:
NCI

Ensembl: ENSG00000203747
- Version: 101_38
Alternate Names:

FCGR3A Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
GuideToPharmacology: 2214
- Version: 29-September-2020
Alternate Names:

3619 HUGO Gene ID

3619 HUGO Gene Symbol

Fc fragment of IgG receptor IIIa HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name CD molecules

GuideToPharmacology Gene Category ID 852

GuideToPharmacology Gene Category Name Immunoglobulin like domain containing proteins

Publications:

PharmGKB: FCGR3A

Version: 18-August-2020

Alternate Names:

PA28065 PharmGKB ID

Gene Info:

Publications:

Nishio M et al., 2009, FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation., Eur J Haematol

Kim SH et al., 2015, Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab., JAMA Neurol

Quartuccio L et al., 2014, The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study., Ann Rheum Dis

DrugBank: BE0002097

Version: 5.1.7

Alternate Names:

FCGR3A DrugBank Gene Name

P08637 UniProt Accession

2214 Entrez Gene Id

Gene Info:

Publications:

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

Zhang et al., 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab., J. Clin. Oncol.

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

NCI: FCGR3A

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology

Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs

Varchetta et al., 2007, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2., Cancer Res.

HingoraniCasas: ENSG00000203747
- Version: 31-May-2017
Alternate Names:

ENSG00000203747 Gene Symbol

FCGR3A Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
GO: FCGR3A
- Version: 05-September-2020
Alternate Names:

CD16A GO Gene Synonym

FCG3 GO Gene Synonym

FCGR3 GO Gene Synonym

Gene Info:

Gene Categories:

EXTERNAL SIDE OF PLASMA MEMBRANE

Publications:
Tempus: FCGR3A
- Version: 11-November-2018
Alternate Names:

FCGR3A Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Immunoglobulin gamma Fc receptor IIIA
- Version: 2020.06.01
Alternate Names:

FCGR3A TTD Gene Abbreviation

T59001 TTD Target ID

Gene Info:

Publications:

3619	HUGO Gene ID
3619	HUGO Gene Symbol
Fc fragment of IgG receptor IIIa	HUGO Gene Name

FCGR3A	DrugBank Gene Name
P08637	UniProt Accession
2214	Entrez Gene Id

FCGR3A Gene Record

FCGR3A 2214 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11556524

Sources: NCI

Interaction Types & Directionality: binder

Interaction Info:

PMIDs: 23866823 28109128 22136436

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12795239 11970990 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19018870 26167726 17324336 23505228 30457672 12975461 15448014 16609067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1418064

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423 24711420

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30457672

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1515095

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17257217

Sources: NCI

Interaction Types & Directionality: ligand

Interaction Info:

PMIDs: 15526004 27463856 19128982 15457442 24048425 27044681

Sources: PharmGKB DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423 24048425 27044681

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 20347527

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19005160 25823782 24048425 27044681

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15217834

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18089830 18347005 21109570 17363544

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23296156 27897268 17139284 17704420 17016423 28719596 30318772

Sources: NCI PharmGKB DrugBank

Interaction Types & Directionality: other/unknown

Interaction Info:

PMIDs: None found

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
11556524

Sources:
NCI

Interaction Types & Directionality:

binder

PMIDs:
23866823 28109128 22136436

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
12795239 11970990 17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
19018870 26167726 17324336 23505228 30457672 12975461 15448014 16609067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
1418064

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423 24711420

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
30457672

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
1515095

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17257217

Sources:
NCI

Interaction Types & Directionality:

ligand

PMIDs:
15526004 27463856 19128982 15457442 24048425 27044681

Sources:
PharmGKB DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423 24048425 27044681

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

PMIDs:
20347527

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
19005160 25823782 24048425 27044681

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15217834

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
18089830 18347005 21109570 17363544

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
23296156 27897268 17139284 17704420 17016423 28719596 30318772

Sources:
NCI PharmGKB DrugBank

Interaction Types & Directionality:

other/unknown

PMIDs:
None found

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
11556524

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17187818

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7662976

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2528593 1827816

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1300984

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8423352

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17139284 17016423 15886877

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17329922

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11772808